New Data Buoy Takeda/Seattle Genetics’ Confidence In Adcetris
This article was originally published in PharmAsia News
Takeda Pharmaceutical and Seattle Genetics have announced new top-line results from the Phase III AETHERA trial with Adcetris in Hodgkin lymphoma that pave the way for a FDA supplementary regulatory filing in this setting sometime next year.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.